



SU International Mathematics Research Meeting

Mathematical Biology Workshop

Stochastic Modeling of HIV Dynamics within an individual and its management

Rachel Waema Mbogo

July, 26 2012



Outline

- Brief overview
- Statement of the problem
- Objectives of the study
- Significance of the study
- Methodology
- Expected outcomes



Brief overview

- Why model HIV/ AIDS
- Interaction of the HIV virus and the immune system of an infected person
- Why stochastic processes



Problem statement

- Eradication of the HIV virus is not attainable with the current available drugs and now the focus is the management and control of the virus progression in an infected person.
- The allocation of the limited budget by the Government to combat the disease.



Research Objectives

Main objective

- To develop stochastic models for the study of HIV internal viral dynamics and its management.

Specific objectives

- Formulate a model for the Virus – host interaction
- Formulate stochastic Models for the progression of the disease
- Formulate a HIV Management Cost (HMC) Model
- Formulate a Cost Benefit Analysis (CBA) Model




Significance of the study

- Stochastic models for the management of the HIV epidemic
 - The analysis of the models will show what treatment combination is effective at what disease state.
 - The cost model will help the government and donors make informed decisions about resource allocation



Methodology


Framework for stochastic processes





Methodology (Cont)


objective 1: HIV – Host interaction dynamics



Research Methodology(cont)



HIV virus –host Interaction dynamics



Rachel (2012)



Possible transitions in HIV - host interactions

Event	Population components (X, Y, V) at t	Population components (X, Y, V) at $(t, t + \Delta)$	probability of transition
Production of uninfected cell	$(x - 1, y, v)$	(x, y, v)	$\lambda\Delta t$
Death of uninfected cell	$(x + 1, y, v)$	(x, y, v)	$\delta(x + 1)\Delta t$
Infection of uninfected cell	$(x + 1, y - 1, v + 1)$	(x, y, v)	$\beta(x + 1)(v + 1)\Delta t$
Production of virons from the dying infected cell	$(x, y + 1, v - 1)$	(x, y, v)	$\kappa N(y + 1)\Delta t$
Introduction of Virons due to re-infection because of risky behaviour	$(x, y, v - 1)$	(x, y, v)	$\gamma\Delta t$
Death of virons	$(x, y, v + 1)$	(x, y, v)	$\mu(v + 1)\Delta t$



The Master equation for Virus-Host interaction

$$\begin{aligned} P'_{x,y,v}(t) &= -\{\lambda + \delta x + \alpha\beta xv + \mu v + \kappa y + \gamma\}P_{x,y,v}(t) \\ &+ \lambda P_{x-1,y,v}(t) \\ &+ \delta(x+1)P_{x+1,y,v}(t) \\ &+ \alpha\beta(x+1)(v+1)P_{x+1,y-1,v+1}(t) \\ &+ N\omega\kappa(y+1)P_{x,y+1,v-1}(t) \\ &+ \gamma P_{x,y,v-1}(t) \\ &+ \mu(v+1)P_{x,y,v+1}(t) \end{aligned}$$



The Lagrange Partial Differential Equation

$$\begin{aligned} \frac{\partial G}{\partial t} = & \{(z_1 - 1)\lambda + (z_3 - 1)\gamma\}G + (1 - z_1)\delta \frac{\partial G}{\partial z_1} + (\omega N z_3 - z_2)\kappa \frac{\partial G}{\partial z_2} \\ & + (1 - z_3)\mu \frac{\partial G}{\partial z_3} + \alpha\beta(z_2 - z_1 z_3) \frac{\partial^2 G}{\partial z_1 \partial z_3} \end{aligned}$$





Moments of $X(t)$, $Y(t)$ and $V(t)$ from the pgf


$$1. \frac{dx}{dt} = \lambda - \delta x(t) - \alpha\beta x(t)v(t)$$

$$2. \frac{dy}{dt} = \alpha\beta x(t)v(t) - \kappa y(t)$$

$$3. \frac{dx}{dt} = \gamma + \omega N \kappa y(t) - \alpha\beta x(t)v(t)$$

Methodology (Cont)

objective 2: HIV virus progression dynamics




Research Methodology(cont)



HIV progression dynamics

- We will assume that the clinical course of untreated HIV infection proceeds through five states:



State 1: ($VL \leq 400$ cp/ml & $CD4 < 200 \times 10^6$ cells/ μ L);

State 2: ($VL \leq 400$ cp/ml & $CD4 > 200 \times 10^6$ cells/ μ L);

State 3: ($VL > 400$ cp/ml & $CD4 > 200 \times 10^6$ cells/ μ L);

State 4: ($VL > 400$ cp/ml & $CD4 < 200 \times 10^6$ cells/ μ L);

State D: Absorbing state; (death of the patient).



Expected outcomes

- Stochastic model for Virus –host interaction
- Markov models to describe the disease internal progression in an infected person
- Transition probabilities that describe the various stages of the disease
- A Disease Management Cost (DMC) model
- Cost Benefit Analysis (CBA) model
- Future Scientific Research



Thank you

